Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based CFO’ operating in the Life Science space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Rebecca Lucia
Partner, Chief Financial Officer & COO of 5AM Ventures
Rebecca joined AMV in 2010 and brought 15 years of experience in finance. She is responsible for accounting, finance and investor relations. Prior to AMV, Rebecca was Director of Finance at CV Therapeutics (“CVT”) until the acquisition of the company by Gilead Sciences in 2009 for $1.4B. At CVT, she oversaw the financial planning function for the company’s Commercial organization, which had a $120M operating budget and 270 employees. Prior to CVT, Rebecca was CFO at CareandHealth in the UK where she managed all finance, legal, HR, and operational functions of the firm. Previously, Rebecca was Director of Investor Relations at Chiron Corporation until its acquisition by Novartis in 2006 at a value of $8.8B. She began her career at Deloitte where she progressed through various positions in audit and financial consulting, most recently as a Senior Manager in the Financial Advisory Services group. Rebecca has an MBA from Kellogg School of Management, a Chartered Financial Analyst designation, and in 1997 she earned a Canadian Chartered Accountant designation.
Follow Rebecca Lucia:
About 5AM Ventures: 5AM Ventures is a venture capital firm that aims to finance seed and early-stage life sciences companies.
Niall O’Cathasaigh
CFO of Prealize Health
As CFO, Niall O’Cathasaigh is the senior executive responsible for sound fiscal management of all financial operations and human resource activities, as well as overseeing capital raising efforts and financial reporting for board and other stakeholder communications. Niall has been working as a founder and consultant with startups and growth stage companies in the US, Europe and Africa for over 20 years. He works with Countsy, an innovative professional services firm that specializes in working with venture funded startups to provide end to end strategic and back office services. His experience includes work with over 30 startups in the Bay Area, with a focus on healthcare companies, providing financial transparency and strategic guidance as well as enabling funding rounds and acquisitions. Niall is also a founder and partner of ManoCap, a private equity fund management company that makes equity investments in small to mid-cap enterprises in West Africa. Prior to that he worked at Apple’s European divisions in Ireland and France. Niall is a qualified financial professional (CIMA). He holds a postgraduate degree in business from University College Dublin, and a joint BA in History and Classical Civilization from University College Galway and Universite De Poitiers.
Follow Niall O’Cathasaigh:
About Prealize Health: Prealize Health uses machine learning to transform healthcare from reactive to proactive.
Glenn S. Boehnlein
Chief Financial Officer & Vice President of Stryker
Follow Glenn S. Boehnlein:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Jaime Bartushak
CFO of Citius Pharmaceuticals
Follow Jaime Bartushak:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Debrah Herman
Chief Financial Officer and Partner of Anzu Partners
Follow Debrah Herman:
About Anzu Partners, BioFlyte: Anzu Partners is an investment firm that invests in industrial and life science technology companies.
Alexander Casdin
Chief Operating Officer & Chief Financial Officer of Epirium
Alexander Casdin is the Chief Financial Officer (CFO) of Epirium Bio. He has broad financial and operational expertise, with more than 20 years of experience as a healthcare executive and investor. Prior to joining Epirium, Mr. Casdin was founder, Chief Executive Officer (CEO) and portfolio manager of Reneo Capital Management LP, a successful healthcare investment fund. He previously served as CFO of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals. Mr. Casdin was a founder and senior advisor at Casdin Advisors, LLC; CEO and portfolio manager at Cooper Hill Partners, LLC, a healthcare investment fund; and portfolio manager of Pequot Capital Management’s healthcare fund. Earlier, he worked at the Dreyfus Corporation as a senior managing analyst covering pharmaceuticals, biotechnology and medical devices. Mr. Casdin has been on the board of directors for multiple life science companies including Erasca, Inc., Dusa Pharmaceuticals, Inc., and Ignyta, Inc. Mr. Casdin received an M.B.A from Columbia Business School and a B.A. in political science from Brown University.
Follow Alexander Casdin:
About Epirium, Epirium: Epirium Bio is a clinical stage bio pharmaceutical company.
Algimantas Chesonis
CFO of Sweetwater Energy
Algimantas Chesonis currently works as Chief Financial Officer at Sweetwater Energy.
Follow Algimantas Chesonis:
About Sweetwater Energy: Sweetwater Energy is a company that produces concentrated sugar from multiple non-food plant materials.
Algimantas Chesonis
CFO of Sweetwater Energy
Algimantas Chesonis currently works as Chief Financial Officer at Sweetwater Energy.
Follow Algimantas Chesonis:
About Sweetwater Energy: Sweetwater Energy is a company that produces concentrated sugar from multiple non-food plant materials.
Arthur Polk
Chief Financial Officer & Co-Founder of PetDx
Arthur Polk is the Chief Financial Officer and a Co-Founder at PetDx.
Follow Arthur Polk:
About PetDx: PetDx is a molecular diagnostics company dedicated to the detection and treatment of cancer in pets.
Daniel Geffken
Interim Chief Financial Officer of CalciMedica
Daniel E. Geffken is the founder and managing director of Danforth Advisors, a consulting firm providing administrative, strategic and operational support to life science companies. He has more than 20 years of experience in the life science industry, with companies ranging from early startups to publicly-traded companies with over $1 billion market capitalizations. Previously, he served as chief operating officer or chief financial officer of four publicly-traded and four privately-held companies, in addition to his consulting clients, and was interim chief executive officer of a medical device company. In these roles, he held management responsibility for finance, accounting, human resources, investor/public relations, facilities, legal, intellectual property and manufacturing functions. Mr. Geffken has raised more than $700 million in equity and debt securities, including a $132 million private placement that was, at the time, the largest private investment in public equity (PIPE) in biotechnology history. Previous to these roles, Mr. Geffken was a principal in a private equity firm, and prior to that position was a certified public accountant (CPA) at KPMG. Mr. Geffken holds a master’s degree in business administration from Harvard Business School and a bachelor’s degree in economics from The Wharton School at the University of Pennsylvania.
Follow Daniel Geffken:
About AnTolRx, Apic Bio, CalciMedica, Danforth Advisors, Danforth Diamond, DermBiont, Elicio Therapeutics, ProMIS Neurosciences, Vigeo Therapeutics, Zikani Therapeutics: CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders.
Michael A. Doyle
Chief Financial Officer of Quanterix
With nearly 30 years of financial and management experience at major companies, Michael serves as Forrester’s chief financial officer (CFO). He leads Forrester’s finance team and oversees the company’s relationships with investors, market analysts, accountants, and bankers. Michael’s responsibilities also include both managing day-to-day financial activity as well as planning for Forrester’s long-term opportunities. Prior to joining Forrester, Michael was CFO of EasyLink Services, a publicly traded global telecommunications messaging provider. There he led an organization focused on improving productivity and financial planning and reporting. Previously, Michael served as CFO at Dun & Bradstreet, North America, responsible for driving the cash flow process improvement to record cash performance, and successfully integrating the Hoovers acquisition. Michael began his career at Continental Can where his tenure included financial management roles at the leading diversified packaging manufacturer. For the next 14 years, he held senior financial management positions at Cendant, Allied Signal, PepsiCo, as well as marketing and strategy positions at Cendant and PepsiCo. Michael holds a Master of Business Administration from New York University and a Bachelor of Business Administration in finance from the University of Notre Dame.
Follow Michael A. Doyle:
About Quanterix: Quanterix is a platform for single molecule analysis that supports clinical diagnostics, drug development, and life science researches.
Jason McCarthy
Chief Financial Officer of Arbor Pharmaceuticals
Jason brings to Arbor over 15 years of progressive accounting, auditing and finance experience from a mixture of public and private companies. Jason most recently managed the accounting function and was responsible for all SEC filings at Lodgian, Inc., an owner and operator of franchised hotels. Prior to Lodgian, Inc., Jason successfully founded his own company specializing in Sarbanes-Oxley implementations and internal control consulting for some of the top public companies in Atlanta. In addition, Jason also worked for PricewaterhouseCoopers in their audit function specializing in real estate and manufacturing. Jason is a Certified Public Accountant in the state of Georgia and a graduate of Ohio University with dual bachelor’s degrees in Accounting and Management Information Systems.
Follow Jason McCarthy:
About Arbor Pharmaceuticals, Sarbanes-Oxley: Arbor Pharmaceuticals is a specialty pharmaceutical company developing late-stage therapeutic products for common pediatric conditions.
James M. O’Brien
Chief Financial Officer of Cognition Therapeutics
James M. O’Brien is the Chief Financial Officer at Cognition Therapeutics.
Follow James M. O’Brien:
About Cognition Therapeutics: Cognition Therapeutics develops new therapeutics to treat patients suffering from Alzheimer’s disease and other neurodegenerative disorders.
David Dillman
CFO of Rev1 Ventures
Dave has responsibility for finance, operations, external reporting and human resources. He also serves as CFO for Rev1’s managed investment funds. Dave came to Rev1 after a career in corporate accounting with the holding company of Alamo, Enterprise and National Car Rental. He’s a skier and mountain biker, who is waiting for our entrepreneurs to invent the transporter so he can teleport back home to Montana for the weekends. Dave has a BS in Accounting from the University of Montana and is an Ohio licensed CPA.
Follow David Dillman:
About Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
Vikram Jog
CFO of Fluidigm
Vikram Jog has served as our Chief Financial Officer since February 2008. From April 2005 to February 2008, Mr. Jog served as Chief Financial Officer for XDx, Inc., a molecular diagnostics company. From March 2003 to April 2005, Mr. Jog was a Vice President of Applera Corporation and Vice President of Finance for its related businesses, Celera Genomics and Celera Diagnostics. From April 2001 to March 2003, Mr. Jog was Vice President of Finance for Celera Diagnostics and Corporate Controller of Applera Corporation. Mr. Jog holds a Bachelor of Commerce degree from Delhi University and an M.B.A. from Temple University. Mr. Jog is a member of the American Institute of Certified Public Accountants.
Follow Vikram Jog:
About Fluidigm: Fluidigm is a biotech tools company that creates microfluidic-based chips and instrumentation for biological research.
Joel Morales
EVP & Chief Financial Officer of Alvotech
Joel Morales is the EVP and Chief Financial Officer at Alvotech.
Follow Joel Morales:
About Alvotech: Setting a new standard in biosimilars
David Chacko
Chief Financial Officer of Erasca
David is Chief Business Officer of Erasca, bringing deep experience in strategy, finance, business development, and operations. He was previously a Principal at Versant Ventures, where he held a dual investing/operating role, helping lead investment opportunities across multiple therapeutic areas. Operationally, he was intimately involved in advancing several Versant portfolio companies through company formation, fundraising, business development, and clinical and regulatory activities. David joined Versant from Alcon, where, as Chief of Staff to the CEO, he worked alongside the executive leadership team to develop and implement high priority corporate initiatives to accelerate growth and innovation. Prior to Alcon, David was an Engagement Manager at McKinsey, leading multiple teams serving pharmaceutical and medical device clients, across sales and marketing, R&D, finance, and other functions. Previously, David worked at SR One, the venture capital arm of GSK. He also worked at Amgen in commercial operations and at Morgan Stanley in investment banking. David holds an M.D. from the University of Pennsylvania, where he was President of the medical student body and an MBA from the Wharton School. He earned an MPhil from Oxford University as a Marshall Scholar, as well as undergraduate degrees in biology and business from the University of Southern California, where he graduated as the University Valedictorian.
Follow David Chacko:
About Erasca: Erasca is a developer of oncology drugs intended to provide precision oncology options.
Kamran Alam
Chief Financial Officer of Taysha Gene Therapies
Kamran Alam is the Chief Financial Officer at Taysha Gene Therapies.
Follow Kamran Alam:
About Taysha Gene Therapies: Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
Matthew Paul
CFO of Boulder Ventures
Matthew Paul joined Boulder Ventures in 2012 as Controller and later a VP of Finance. In these roles, Mr. Paul was responsible for all finance, compliance, and management company operations. Prior to Boulder Ventures, Mr. Paul worked as a Senior Associate and Associate at PricewaterhouseCoopers on various public and private clients across several industries, including: venture capital, private equity, telecommunications, retail, manufacturing, and mining. Mr. Paul is a Certified Public Accountant in the state of Colorado, holds a Master of Accountancy from Colorado State University (2007) and MS in Accounting from Colorado State University (2006).
Follow Matthew Paul:
About Boulder Ventures: Boulder Ventures invests in early stage information technology and life science companies in Colorado and the Mid-Atlantic.
Ivan Ivankovich
CFO of Sanguine
Co-Founder of Full Stack Finance.
Follow Ivan Ivankovich:
About Full Stack Finance, LLC, Markaaz, Sanguine: Sanguine develops innovative technology solutions for clinical researchers.
Hodges Mauri
Vice President, Finance and Administration, Chief Financial Officer and Treasurer of Catalyst Biosciences
Ms. Hodges joined Targacept in August 2000 and currently serves as Vice President, Finance and Administration, Chief Financial Officer and Treasurer. Ms. Hodges was previously Vice President, Human Resources and Corporate Systems and served as Controller for over thirteen years. Ms. Hodges has over eighteen years of biotech and information technology industry experience in the areas of finance, audit, strategy, corporate governance, facilities management, and public company preparedness and oversight. She began her career working in public accounting with Deloitte, Haskins and Sells, and as an entrepreneur, owned and operated a certified public accounting firm for over eight years. She is a member of the World at Work organization, American Institute of Certified Public Accountants and the North Carolina Association of Certified Public Accountants. Ms. Hodges received a B.S. in Business Administration and Accounting from Virginia Polytechnic Institute and State University.
Follow Hodges Mauri:
About Catalyst Biosciences: Catalyst Biosciences is a drug R&D company creating catalytic biopharmaceutical products based on engineered human proteases.
Hodges Mauri
Vice President, Finance and Administration, Chief Financial Officer and Treasurer of Catalyst Biosciences
Ms. Hodges joined Targacept in August 2000 and currently serves as Vice President, Finance and Administration, Chief Financial Officer and Treasurer. Ms. Hodges was previously Vice President, Human Resources and Corporate Systems and served as Controller for over thirteen years. Ms. Hodges has over eighteen years of biotech and information technology industry experience in the areas of finance, audit, strategy, corporate governance, facilities management, and public company preparedness and oversight. She began her career working in public accounting with Deloitte, Haskins and Sells, and as an entrepreneur, owned and operated a certified public accounting firm for over eight years. She is a member of the World at Work organization, American Institute of Certified Public Accountants and the North Carolina Association of Certified Public Accountants. Ms. Hodges received a B.S. in Business Administration and Accounting from Virginia Polytechnic Institute and State University.
Follow Hodges Mauri:
About Catalyst Biosciences: Catalyst Biosciences is a drug R&D company creating catalytic biopharmaceutical products based on engineered human proteases.
Richard Lindahl
Executive Vice President & Chief Financial Officer of Emergent BioSolutions
Rich Lindahl currently serves as the executive vice president and chief financial officer at Emergent BioSolutions.
Follow Richard Lindahl:
About Corporate Executive Board (CEB), Emergent BioSolutions: Emergent BioSolutions develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats.
Gavin Wood
Chief Financial Officer of Abcam
Gavin is a chartered accountant who started his career in practice in London before moving to Grant Thornton’s Thames Valley office. Gavin was Executive Vice President and Chief Financial Officer in 2013. Gavin joined Affymetrix in 2006 and has held a number of financial roles, including Vice President, Finance, International Controller, responsible for Europe and Asia Pacific. Prior to joining Affymetrix, Gavin held a number of positions at the Unipart Group of Companies, including Business Unit Controller and Business Process Manager for implementing major enterprise resource planning systems in North America. Gavin has over twenty years’ experience as an accounting professional with broad, and international exposure in a number of sectors and roles including Corporate, Statutory and Operational accounting, Project Management and Investor Relations. Gavin is a Chartered Accountant who qualified with the London Accountancy Practice Morgan Brown Spofforth in 1997 before continuing his career with Grant Thornton LLP.
Follow Gavin Wood:
About Abcam: An innovator in life science reagents and tools serving life science researchers globally to achieve their mission, faster.
Knud Mueller
Sr. Vice President & Chief Financial Officer of Beckman Coulter
Follow Knud Mueller:
About Beckman Coulter: Beckman Coulter develops, manufactures and markets products that simplify & automate biomedical testing for lab professionals.
Douglas J. Swirsky
Chief Financial Officer of AavantiBio
Follow Douglas J. Swirsky:
About AavantiBio, TrAMPoline Pharma: AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.
John Cavan
CFO of Hepion Pharmaceuticals
John Cavan brings more than 20 years of financial management experience in both public and private companies. Prior to joining Hepion as CFO, Mr. Cavan was a consultant with The Pine Hill Group where he was instrumental in completing several financial transactions, including initial public offerings, business combinations and strategic transactions. Prior to his role with the Pine Hill Group, he served as Chief Accounting Officer at Stemline Therapeutics, Inc. Preceding his role at Stemline, Mr. Cavan was Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals, Inc. where he was instrumental in the company’s initial public offering, through which Aegerion achieved a $2 billion market capitalization. He has also held financial positions within the healthcare industry at AlgoRx Pharmaceuticals, Inc. and Alpharma. Mr. Cavan served in a variety of financial and operational positions early in his career during tenures with large multinational public companies, including Sony, American Express, International Specialty Products (an Ashland Company) and Nestlé U.S.A. Mr. Cavan currently serves on the Board of Directors of Vantage Health Systems. He holds a B.B.A in Accountancy from Iona College and an M.B.A. in Finance from Seton Hall University.
Follow John Cavan:
About Hepion Pharmaceuticals: Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for liver disease.
Matthew Navarro
Chief Financial Officer of Glympse Bio
Follow Matthew Navarro:
About Glympse Bio: Glympse Bio is a biotechnology company that transforms disease detection and predict treatment response.
Lindon Robertson
EVP and CFO of Brooks Automation
Mr. Robertson joined Brooks on October 1, 2013 as Executive Vice President and Chief Financial Officer. Mr. Robertson is responsible for leading and managing Brooks’ global financial strategy including establishing long range financial planning and policies while maintaining positive relationships with their shareholders and the financial community. Prior to joining Brooks, Mr. Robertson was Vice President and Chief Financial Officer of Graftech International, a $1.3 billion global provider of carbon and graphite products for industrial applications. Prior to Graftech International, he worked for the IBM Corporation for over 25 years in various senior financial management roles, including CFO of IBM’s global hardware business and CFO of IBM’s Japan and China operations. Mr. Robertson holds an MBA from the University of North Carolina, Chapel Hill and an undergraduate degree in accounting from the University of Texas, Austin. He also holds a CPA license from the state of North Carolina.
Follow Lindon Robertson:
About Brooks Automation: Brooks Automation provides automation, vacuum, and instrumentation solutions to the worldwide semiconductor manufacturing industry.
Jan Bertsch
Executive Vice President and Chief Financial Officer of MilliporeSigma
Jan Bertsch leads O-I’s financial and information technology functions, including finance and accounting, corporate reporting, corporate tax, treasury, investor relations, internal audit and IT. She is focused on maintaining the financial flexibility of the company, as well as ensuring the company’s strategic initiatives and capital allocation philosophy deliver appropriate shareholder value. Working to increase connectivity and efficiency, Bertsch is also responsible for the delivery of technology solutions focused on collaboration. Bertsch joined O-I in 2015, bringing extensive experience as an operationally-focused CFO with a solid track record of value creation and asset optimization across various manufacturing companies.
Follow Jan Bertsch:
About MilliporeSigma, O-I Glass: MilliporeSigma is a technology company that develops, manufactures, and distributes various biochemicals and organic chemicals.
John C. Oakley
CFO of KNOW Bio
John C. Oakley is the CFO at KNOW Bio.
Follow John C. Oakley:
About KNOW Bio, Vast Therapeutics: KNOW Bio, LLC develops and produces nitric oxide-based therapies.
John C. Oakley
CFO of KNOW Bio
John C. Oakley is the CFO at KNOW Bio.
Follow John C. Oakley:
About KNOW Bio, Vast Therapeutics: KNOW Bio, LLC develops and produces nitric oxide-based therapies.
Michael A. Schulz
Chief Financial Officer & Head of Finance, Crop Science Division of Bayer CropScience
Michael Schulz is a member of the Executive Committee of Bayer CropScience. As the company’s Chief Financial Officer he is responsible for Business Planning & Administration since July, 1, 2011. Michael Schulz, born on March 3, 1965 in Mannheim, Germany, started his professional career in commercial banking. He graduated from Mannheim University after studying Economics and Business Administration. From 1992 to 2000 Michael Schulz worked with Gemini Consulting on a variety of assignments in the Consumer Goods and Health industries. In 2001 he joined Cap Gemini Ernst & Young in the U.S. where he led the Life Sciences Strategy practice working for major industry clients. In 2006 he joined Bayer AG Corporate Development being responsible for Bayer HealthCare Strategy. Since December 2007 Michael Schulz was responsible for Business Planning & Administration of Bayer HealthCare’s Animal Health Division in Monheim.
Follow Michael A. Schulz:
About Bayer CropScience: Bayer CropScience is a company specializing in agriculture, healthcare, and life sciences.
John Borgeson
Chief Financial Officer of ALX Oncology
John Borgeson is our Chief Financial Officer and has served in this position since June 2014. Borgeson brings over 25 years of pharmaceutical industry experience in finance, strategy and operations on a global scale. Previously Borgeson was a Vice President of Finance at Pfizer and a member of Pfizer’s Global Financial Leadership Team. Borgeson’s roles at Pfizer included CFO for Pfizer’s biotherapeutics division and corporate tax executive with responsibility for US and Europe. Under Borgeson’s leadership, Pfizer completed a transformational restructuring of the global tax group that was replicated by other Fortune 50 companies. Borgeson has more recently led finance for a variety of private biotech companies, including Labrys Biologics, which was acquired by Teva Pharmaceuticals for $825 million. He was also CFO of venBio, a venture capital firm with a strong track record in biotechnology investing. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant. He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).
Follow John Borgeson:
About ALX Oncology, Kodiak Sciences: ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
William Harris
CFO of EnGeneIC
Follow William Harris:
About EnGeneIC: EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.
James Clavijo
Chief Financial Officer of Longeveron
James Clavijo is the Chief Financial Officer at Longeveron.
Follow James Clavijo:
About Longeveron: Longeveron is a life-sciences company that develops biological solutions for aging and aging-associated diseases.
Byron Wittenberg
COO & CFO of Epivara
Byron Wittenberg serves as the Chief Operating and Financial Officer at Epivara.
Follow Byron Wittenberg:
About Epivara: Epivara provides a single-injection alternative to spay and neuter surgery.
Katina Dorton
CFO of NodThera
Katina is a seasoned investment banker with over 20 years of Wall Street experience. She spent most of her career at Morgan Stanley, where she was a Managing Director in Corporate Finance. Previously, Katina was an attorney focused on M&A and securities matters. At Morgan Stanley, Katina worked in the Media/ Communications Group where she advised both large and emerging companies on capital raising and M&A. Katina spent two years as a senior banker in Morgan Stanley’s office in Frankfurt, Germany, where she worked with many European communications and media companies. Prior to Morgan Stanley, Katina practiced law in New York with Sullivan & Cromwell. After Morgan Stanley, Katina was Managing Director with Needham& Co, a boutique investment bank in New York. Most recently, Katina was a Senior Advisor to one of the predecessor firms of CoRise (DreamTigerEquities), and has worked with a number of entrepreneurial companies. Katina currently serves as a Senior Mentor in the CED’s Venture Mentoring Serivices, a mentoring service for start-up companies that is run in conjunction with MIT. Katina received an undergraduate degree in Economics from Duke University, a J.D. degree from the University of Virginia, and an MBA from George Washington University.
Follow Katina Dorton:
About NodThera: NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases.
John Leaman
CFO of Aevi Genomic Medicine
John Leaman joined Medgenics as CFO in September 2013. Prior to joining Medgenics, Dr. Leaman served as VP of Commercial Assessment at Shire plc, a global specialty pharmaceutical company, with responsibility for the strategic assessment of licensing and M&A opportunities, including Shire’s acquisition of SARcode Bioscience Inc. Prior to joining Shire in 2011, from 2007 to 2011, Dr. Leaman was a Principal at Devon Park Bioventures, a venture capital fund targeting investments in therapeutics companies, where he oversaw the fund’s investment and corporate board duties in life science investments including Proteon Therapeutics, Inc., Inotek Pharmaceuticals Corp., ZS Pharma, Inc. and MicuRx Pharmaceuticals, Inc. Prior to that, he was an Associate Principal at McKinsey & Company, where he provided consulting services to senior management of several top 20 pharmaceutical companies including M&A and corporate finance, payer/reimbursement strategies and strategic product development. He received an M.D. and an M.B.A. from the University of Pennsylvania’s School of Medicine and Wharton School, respectively. He received a degree in Psychology, Philosophy and Physiology at Oriel College, University of Oxford, while completing a Rhodes scholarship. Dr. Leaman received a B.S. in biology from Elizabethtown College.
Follow John Leaman:
About Aevi Genomic Medicine: Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies.
Clay Anderson
Chief Financial Officer of RoverMed BioSciences
Anderson is an extremely knowledgeable professional in the finance and pharmaceutical sectors. Mr. Anderson’s value to the RoverMed organization has been formed through decades of experience with pharmaceutical and technology organizations. With a focus on financial performance, he has been both a founder and CFO in organizations such as Vail Scientific, Verde Technologies, and Travanti Pharma. He has been a co-founder of numerous entrepreneurial enterprises, and has helped lead them from start-up to sale.
Follow Clay Anderson:
About RoverMed BioSciences: RoverMed has developed precision targeted nanocapsule technology aimed at delivering life saving drugs to the most challenging disease sites
Dan Shore
Chief Financial Officer of Broad Institute
Dan Shore is the chief financial officer of the Broad Institute of MIT and Harvard. He focuses on financial strategy and operations with the aim of propelling great science. Previously, Shore served as the integration lead at Brandwatch, a consumer insight analytics company, guiding their merger with Crimson Hexagon. Prior to the merger, Shore led Crimson Hexagon’s finance team as SVP and CFO. Shore also served as CFO at Onshape, a CAD software company. Before his time in the tech sector, Shore was CFO at Harvard University from 2008 to 2014, where he shepherded the university through the global financial crisis. Before the CFO appointment, he served as Harvard’s director of the Office of Budgets and Financial Planning. There, he established the university’s multi-year financial planning process and helped launch the Harvard Corporation committee on finance. He fostered new approaches to a range of financial challenges, including managing liquidity and debt, funding major initiatives and capital projects, and procuring goods and services. Previously, Shore was a consultant at McKinsey & Company and a corporate attorney at Nutter McClennen & Fish. Shore earned his B.A. from Duke University, his J.D. from the University of Pennsylvania, and his M.B.A. from the University of Virginia.
Follow Dan Shore:
About Broad Institute: The Broad Institute brings together a diverse group of individuals from across its partner institutions to confront biomedical challenges.
Molly Henderson
Chief Financial Officer of UroGen Pharma
Molly Henderson is the Chief Financial Officer at UroGen Pharma.
Follow Molly Henderson:
About UroGen Pharma: UroGen Pharma is a clinical-stage biopharmaceutical company.
Daniel Clark
Interim Chief Financial Officer of Kiromic Biopharma
On September 30, 2021, the Board of Directors of the Company appointed Dan Clark as interim Chief Financial Officer, effective September 30, 2021. Mr. Clark joined the Company in February 2020 and served as the Company’s Corporate Controller until September 2021, when he was promoted to Vice President – Finance Operations prior to his appointment as interim Chief Financial Officer. Before joining the Company, Mr. Clark was a Manager with The Siegfried Group, a national accounting services firm, from June 2018 to February 2020. Prior to his employment with The Siegfried Group, Mr. Clark served as Senior Consultant – Office of the CFO Solutions for FTI Consulting, a global financial consulting firm, from January 2017 to May 2018. Prior to that, Mr. Clark was Senior Associate – Audit at KPMG US, a member of Big Four global accounting firm KPMG, from August 2011 to June 2015.
Follow Daniel Clark:
About Kiromic Biopharma: Kiromic develops biomarker- and small molecule-based diagnostic and therapeutic programs for solid tumors and hematologic malignancies.
Sally DelBeccaro
Chief Financial Officer, Senior Partner of WittKieffer
Sally DelBeccaro, Chief Financial Officer & Senior Partner, oversees the firm’s fiscal health, investment in new practices, and capital planning to drive profitable growth. As a key member of the executive management team, she plays an important role in the formation of strategic alliances, legal and compliance matters, internal control, tax planning, and financial strategy. She joined Witt/Kieffer in 2001 after serving in the professional services and healthcare fields. She is based in the firm’s headquarters in Oak Brook, IL. A certified public accountant, Sally holds an M.B.A. from the University of Chicago. Prior to joining the firm, Sally was in the audit division of Peat Marwick, working in the banking and finance industry, and with major transportation and manufacturing clients. After leaving public accounting, Sally was drawn to the healthcare field and entered hospital administration. She worked extensively with medical staffs, insurance carriers, and physician organizations to develop managed care networks on behalf of both hospitals and medical groups. Sally has a deep passion and appreciation for the primary industries served by Witt/Kieffer; healthcare and education. She served for eight years as the president of her local school board and has been actively involved in fundraising activities and volunteer leadership roles for foundations and service organizations benefitting local children’s hospitals.
Follow Sally DelBeccaro:
About WittKieffer: WittKieffer is a global executive search firm dedicated to organizations that improve quality of life in healthcare, education, and more.
R. Scott Areglado
SVP and Chief Financial Officer of Brainsway
Scott Areglado is the SVP and Chief Financial Officer at BrainsWay.
Follow R. Scott Areglado:
About Brainsway, iCAD: Brainsway’s patented breakthrough technology launches a new era in brain disorder treatment.
Alan A. Bucher,
Chief Financial Officer of Getinge
Alan A. Bucher is the Chief Financial Officer at Getinge.
Follow Alan A. Bucher,:
About Getinge: Getinge identifies customer issues and promotes clinical and economic benefits and follow and support the customer decision process.
Chris Dorsey
CFO and COO of Getinge
Chris Dorsey is the CFO and COO at Getinge.
Follow Chris Dorsey:
About Getinge: Getinge identifies customer issues and promotes clinical and economic benefits and follow and support the customer decision process.
Jim Jungwirth
Co-Founder, Vice President, CFO of Harbor MedTech
Follow Jim Jungwirth:
About Harbor MedTech: Harbor MedTech develops and commercializes tissue regeneration products for chronic wounds, hernia and joint repair, and more.
Kurt Dinkelacker
Executive Vice President & Chief Financial Officer of Aptuit LLC
Follow Kurt Dinkelacker:
About Aptuit LLC: Aptuit LLC is a contract research organization.
David Garrett
CFO of Dynacure
David Garrett joins Dynacure from Nabriva Therapeutics, Inc. where he held various roles including VP, Corporate Controller and Head of Investor Relations and Sr. Director, Business Planning and Analysis. At Nabriva, Mr. Garrett led all Wall-Street facing activities, completed over $150M in equity capital raises, and oversaw all SEC reporting and compliance functions. Mr. Garrett was also responsible for leading Nabriva’s redomicile from Austria to Ireland. Prior to Nabriva, Mr. Garrett held senior-level finance roles at Covis Pharmaceuticals, Inc., Auxilium Pharmaceuticals, Inc., and ViroPharma Incorporated and was a manager at KPMG, LLP. Mr. Garrett received an MBA and BS in Accountancy from Villanova University and is a Certified Public Accountant in Pennsylvania.
Follow David Garrett:
About Dynacure, iECURE: Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.
Peter Scott
CFO of CellDrop Biosciences
Peter Scott currently works as the CFO for CellDrop Biosciences.
Follow Peter Scott:
About CellDrop Biosciences: CellDrop Biosciences develops hydrogel-based point-of-care diagnostics and targeted biomaterial delivery technology.
Brian Jackson
Director and Chief Financial Officer of St. Teresa Medical
Mr. Jackson co-founded St. Teresa Medical in 2010. Mr. Jackson has a strong background in early-stage medical technology finance and governance. He has helped raise growth capital in a variety of transactions including public offerings, private placements, venture placements, strategic partnerships, limited partnerships and traditional bank financings. Mr. Jackson co-founded PepTx, a bio-pharmaceutical firm and served as Chairman, President and CEO and later as VP and CFO. Mr. Jackson also served as CFO and Controller for Everest Medical Corporation. Mr. Jackson holds a B.S.B. from the University of Minnesota. Mr. Jackson is the co-inventor on one U.S. patent in cardiovascular technology and another in hemostasis technology.
Follow Brian Jackson:
About St. Teresa Medical: St. Teresa Medical is a medical applications developing company commercializing a hemostatic technology platform called FASTCLOT.
Tom Gruber
COO and CFO of CDx Life
Tom has over 20 years of experience in financial and senior executive management from well known, publicly traded technology companies. He has worked as the CFO for Western Digital and as the CFO and COO for I/O Magic. Tom holds an MBA from Pepperdine University.
Follow Tom Gruber:
About CDx Life: MyDx (My Diagnostic) is the world’s first portable analyzer for everyone – a simple and affordable device.
